ALX Oncology (NASDAQ:ALXO) Stock Price Up 6.8%

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) were up 6.8% on Tuesday . The company traded as high as $17.03 and last traded at $16.85. Approximately 423,219 shares were traded during trading, a decline of 7% from the average daily volume of 453,228 shares. The stock had previously closed at $15.78.

Analyst Ratings Changes

Several equities analysts have commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a research report on Wednesday, April 10th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.83.

ALX Oncology Stock Up 11.3 %

The stock’s 50-day moving average price is $13.67 and its 200-day moving average price is $12.65. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05. The stock has a market cap of $878.00 million, a price-to-earnings ratio of -4.50 and a beta of 1.30.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, sell-side analysts expect that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Jaume Pons sold 50,000 shares of ALX Oncology stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now owns 604,205 shares in the company, valued at approximately $8,579,711. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Jason Lettmann purchased 4,400 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were acquired at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the sale, the insider now owns 604,205 shares of the company’s stock, valued at approximately $8,579,711. The disclosure for this sale can be found here. 50.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ALX Oncology

A number of large investors have recently modified their holdings of the company. Vestal Point Capital LP bought a new stake in ALX Oncology during the 4th quarter worth approximately $24,643,000. TD Asset Management Inc bought a new stake in ALX Oncology during the fourth quarter worth $1,048,000. abrdn plc purchased a new stake in ALX Oncology in the 4th quarter valued at $986,000. Swiss National Bank bought a new position in ALX Oncology during the 1st quarter valued at $493,000. Finally, Hsbc Holdings PLC purchased a new position in ALX Oncology during the 3rd quarter worth $168,000. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.